2024
An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study
Dunn W, Li Y, Singal A, Simonetto D, Díaz L, Idalsoaga F, Ayares G, Arnold J, Ayala-Valverde M, Perez D, Gomez J, Escarate R, Fuentes-López E, Ramirez-Cadiz C, Morales-Arraez D, Zhang W, Qian S, Ahn J, Buryska S, Mehta H, Dunn N, Waleed M, Stefanescu H, Bumbu A, Horhat A, Attar B, Agrawal R, Cabezas J, Echavaría V, Cuyàs B, Poca M, Soriano G, Sarin S, Maiwall R, Jalal P, Higuera-de-la-Tijera F, Kulkarni A, Rao P, Guerra-Salazar P, Skladaný L, Kubánek N, Prado V, Clemente-Sanchez A, Rincon D, Haider T, Chacko K, Romero G, Pollarsky F, Restrepo J, Toro L, Yaquich P, Mendizabal M, Garrido M, Marciano S, Dirchwolf M, Vargas V, Jiménez C, Hudson D, García-Tsao G, Ortiz G, Abraldes J, Kamath P, Arrese M, Shah V, Bataller R, Arab J. An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study. Hepatology 2024, 80: 1196-1211. PMID: 38607809, DOI: 10.1097/hep.0000000000000883.Peer-Reviewed Original ResearchAlcohol-associated hepatitisValidation cohortArtificial intelligenceModified Glasgow scoreMaddrey's discriminant functionMortality rateGlobal cohort studyShort-term mortalityPost-test probabilityApproximate mortality ratesSteroid therapyGlasgow scoreAH patientsSteroid useTransplant indicationRetrospective studyDerivation cohortLaboratory valuesCohort studyClinical trialsGlobal cohortPrognostic modelScoring systemAI algorithmsCohort
2023
MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis
Díaz L, Fuentes-López E, Ayares G, Idalsoaga F, Arnold J, Valverde M, Perez D, Gómez J, Escarate R, Villalón A, Ramírez C, Hernandez-Tejero M, Zhang W, Qian S, Simonetto D, Ahn J, Buryska S, Dunn W, Mehta H, Agrawal R, Cabezas J, García-Carrera I, Cuyàs B, Poca M, Soriano G, Sarin S, Maiwall R, Jalal P, Abdulsada S, Higuera-de-la-Tijera F, Kulkarni A, Rao P, Salazar P, Skladaný L, Bystrianska N, Clemente-Sanchez A, Villaseca-Gómez C, Haider T, Chacko K, Romero G, Pollarsky F, Restrepo J, Castro-Sanchez S, Toro L, Yaquich P, Mendizabal M, Garrido M, Marciano S, Dirchwolf M, Vargas V, Jiménez C, Louvet A, García-Tsao G, Roblero J, Abraldes J, Shah V, Kamath P, Arrese M, Singal A, Bataller R, Arab J. MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis. JHEP Reports 2023, 5: 100727. PMID: 37456675, PMCID: PMC10339256, DOI: 10.1016/j.jhepr.2023.100727.Peer-Reviewed Original ResearchRenal replacement therapy requirementAlcohol-associated hepatitisMaddrey's discriminant functionShort-term mortalityFurther prospective studiesMELD-NaTherapy requirementsProspective studyEnd-stage liver diseaseHigh short-term mortalityGlobal cohortRetrospective cohort studyCompeting-risk analysisTime-dependent AUCMELD-sodiumLiver transplantationMalnourished patientsCohort studyEstablishment of treatmentLiver diseaseABIC scoreLargest global cohortMAIN OUTCOMEMortality predictionDeLong method